HR and breast cancer: RIGHT Choice was a randomized phase 2 clinical trial of ribociclib plus letrozole plus goserelin that explored the efficacy and safety of this combination versus chemotherapy in pre-/perimenopausal women with clinically aggressive HR+/HER2− advanced breast cancer.